Nonsteroidal Anti-inflammatory Drugs in Ophthalmology

Kim, Stephen J.; Flach, Allan J.; Jampol, Lee M.

doi:10.1016/j.survophthal.2009.07.005

Cited by 333 publications

(343 citation statements)

References 315 publications

Supporting

Mentioning

316

Contrasting

Unclassified

Order By: Relevance

“…24 The diffraction profile obtained confirmed the DSC data evidencing that the drug was amorphous inside polymeric nanoparticles. 2 …”

Section: Nanoparticles Characterizationmentioning

confidence: 99%

Encapsulation of naproxen in nanostructured system: structural characterization and in vitro release studies

Mello¹,

Ricci-Júnior²

2011

Quím. Nova

View full text Add to dashboard Cite

Recebido em 7/6/10; aceito em 10/1/11; publicado na web em 25/3/11 Nanoparticles were produced by solvent emulsification evaporation method with the following characteristics: nanometric size (238 ± 3 nm), narrow polydispersity index (0.11), negative zeta potential (-15.1 mV), good yield of the process (73 ± 1.5%), excellent encapsulation efficiency (81.3 ± 4.2%) and spherical shape. X-rays diffraction demonstrated the loss of drug crystallinity after encapsulation; however, the profile of the diffractograms of the poly-ε-caprolactone (PCL) nanoparticles was kept. Differential scanning calorimetry thermograms, correspondingly, exhibited the loss of drug melting peak and the increasing of the melting point of the PCL nanoparticles, evidencing an interaction drug-polymer. Naproxen release was low and sustained obeying the Higuchi´s kinetic. The results show that nanoparticles are promising sustained release system to the naproxen.

show abstract

“…24 The diffraction profile obtained confirmed the DSC data evidencing that the drug was amorphous inside polymeric nanoparticles. 2 …”

Section: Nanoparticles Characterizationmentioning

confidence: 99%

Encapsulation of naproxen in nanostructured system: structural characterization and in vitro release studies

Mello¹,

Ricci-Júnior²

2011

Quím. Nova

View full text Add to dashboard Cite

show abstract

“…Topical NSAIDS are primarily used for inflammatory ocular conditions such as the suppression of uveitis that may be present before and after intraocular surgery http://www.openveterinaryjournal.com R. Cantarella et al Open Veterinary Journal, (2017), Vol. 7(3): 254-260 ________________________________________________________________________________________________________ 255 (Giuliano, 2004;Sigle and Nasisse, 2006;Kim et al, 2010;Maca et al, 2010;Klein et al, 2011). Chen et al (1997) showed that the application of topical NSAID ophthalmic solutions effectively reduced corneal sensitivity as well as the sensitivity of polymodal nociceptors.…”

Section: Introductionmentioning

confidence: 99%

Effects of topical flurbiprofen sodium, diclofenac sodium, ketorolac tromethamine and benzalkonium chloride on corneal sensitivity in normal dogs

Cantarella¹,

Oliveira²,

Dorbandt³

et al. 2017

Open Vet J.

View full text Add to dashboard Cite

To evaluate corneal sensitivity by using the Cochet-Bonnet® esthesiometer in normal canine eyes at different time points following instillation of three different topical non-steroidal anti-inflammatory drugs (flurbiprofen sodium 0.03%, diclofenac sodium 0.1% and ketorolac tromethamine 0.5%) and benzalkonium chloride 0.01%. Six healthy mixed breed dogs from the same litter were used in two different stages. First, one drop of flurbiprofen sodium 0.03% and diclofenac sodium 0.1% in each eye; second, one drop of ketorolac tromethamine 0.5% and benzalkonium chloride 0.01% in each eye. Baseline esthesiometry was obtained before eye drop application and every 15 minutes thereafter until a total of 105 minutes of evaluation time. A one-week interval was allowed between the two treatment phases. Statistical analysis was used to compare means according to time of evaluation and drug used. Diclofenac sodium 0.1% decreased corneal sensitivity at 75 and 90 minutes (P > 0.015) with possible interference on neuronal nociceptive activity and analgesic effect while ketorolac tromethamine 0.5% did not show any variation for esthesiometry means along the evaluation. Flurbiprofen sodium 0.03% resulted in increased esthesiometry values 30 minutes after instillation (P > 0.013), increasing corneal sensitivity and possibly producing a greater irritant corneal effect over its analgesic properties. Benzalkonium chloride 0.01% significantly increased corneal sensitivity at 15 minutes of evaluation (P > 0.001), most likely resulting from its irritating effect. Esthesiometry did not allow a definite conclusion over the analgesic effect of the NSAIDs tested; however it was effective in detecting fluctuations in corneal sensitivity.

show abstract

“…In ophthalmology, topical NSAIDs are used to stabilize pupillary dilation during intraocular surgery and to treat allergic conjunctivitis and postoperative inflammation, pain and cystoid macular edema (CME). (12)(13)(14)(15)(16)(17) If an NSAID can penetrate to the retina, it could possibly reduce vascular permeability by inhibiting the inflammatory cascade. Based on this hypothesis, patients with DME may benefit from topical nepafenac 0.1% in an attempt to reduce the edema and improve vision.…”

Section: Introductionmentioning

confidence: 99%

Comparative Study of Intravitreal Ranibizumab with and Without Nepafenac Eye Drops for Center Involving Diabetic Macular Edema

Shousha¹,

Helaly²

2015

jmscr

View full text Add to dashboard Cite

Nonsteroidal Anti-inflammatory Drugs in Ophthalmology

Cited by 333 publications

References 315 publications

Encapsulation of naproxen in nanostructured system: structural characterization and in vitro release studies

Encapsulation of naproxen in nanostructured system: structural characterization and in vitro release studies

Effects of topical flurbiprofen sodium, diclofenac sodium, ketorolac tromethamine and benzalkonium chloride on corneal sensitivity in normal dogs

Comparative Study of Intravitreal Ranibizumab with and Without Nepafenac Eye Drops for Center Involving Diabetic Macular Edema

Contact Info

Product

Resources

About